Table 1 General characteristics of patients.
rhTPO group (n=26) | Control group (n=14) | p value | |
|---|---|---|---|
Median age, years (range) | 54.46 (36–70) | 52.93 (45–59) | 0.539 |
Sex, n (%) | 1.000 | ||
Male | 18 (69.2%) | 10 (71.4%) | |
Female | 8 (30.8%) | 4 (28.6%) | |
Induction therapy protocol | VRD | VRD | – |
DS staging, n (%) | 1.000 | ||
I | 0 | 0 | |
II | 2 (7.7%) | 1 (7.1%) | |
III | 24 (92.3%) | 13 (92.9%) | |
IV | 0 | 0 | |
ISS staging, n (%) | 0.140 | ||
I | 7 (26.9%) | 11 (78.6%) | |
II | 10 (38.4%) | 7 (50%) | |
III | 9 (34.6) | 3 (21.4%) | |
R-ISS staging, n (%) | 0.631 | ||
I | 7 (26.9%) | 4 (28.6%) | |
II | 12 (46.2%) | 8 (57.1%) | |
III | 7 (26.9%) | 2 (14.3%) | |
Classification of active MM (mSMART 3.0), n (%) | 0.973 | ||
High-risk | 15 (57.7%) | 8 (57.1%) | |
Standard-risk | 11 (42.3%) | 6 (42.9%) | |
Pre-transplant condition, n (%) | 0.185 | ||
CR | 14 (69.7%) | 11 (78.6%) | |
VGPR | 11 (24.2%) | 2(14.3%) | |
PR | 1 (6.1%) | 1 (7.1%) |
